The thioacetate-ω(γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent

Antiviral Research

Volumn 123, Issue , 2015, Pages 62-69

  Badia, Roger ^a   Grau, Judith ^a   Riveira Muñoz, Eva ^a   Ballana, Ester ^a   Giannini, Giuseppe ^b   Esté, José A ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Sigma Tau SpA   (Italy)

Author keywords

HDAC; HIV; Latency; Reactivation; Shock and kill

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; PLERIXAFOR; RALTEGRAVIR; ROMIDEPSIN; ST 7612AA 1; THIOACETATE OMEGA(GAMMA LACTAM CARBOXAMIDE)DERIVATIVE; THIOL DERIVATIVE; UNCLASSIFIED DRUG; VORINOSTAT; 2 PYRROLIDONE DERIVATIVE; ANILIDE; ANTIRETROVIRUS AGENT; DEPSIPEPTIDE; HYDROXAMIC ACID; INDOLE DERIVATIVE; THIOACETIC ACID S-(6-((5-OXOPYRROLIDINE-2-CARBONYL)AMINO)-6-PHENYLCARBAMOYLHEXYL) ESTER;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LATENT VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS TRANSCRIPTION; CELL CULTURE; CELL PROLIFERATION; COMPARATIVE STUDY; DRUG EFFECTS; DRUG INTERACTION; MALE; METABOLISM; MONONUCLEAR CELL; PHYSIOLOGY; VIROLOGY;

ANILIDES; ANTI-RETROVIRAL AGENTS; CELL PROLIFERATION; CELLS, CULTURED; DEPSIPEPTIDES; DRUG INTERACTIONS; HISTONE DEACETYLASE INHIBITORS; HIV-1; HUMANS; HYDROXAMIC ACIDS; INDOLES; LEUKOCYTES, MONONUCLEAR; MALE; PYRROLIDINONES; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84941215028     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.09.004     Document Type: Article

References (33)

1. N.M. Archin, A.L. Liberty, A.D. Kashuba, S.K. Choudhary, J.D. Kuruc, A.M. Crooks, D.C. Parker, E.M. Anderson, M.F. Kearney, M.C. Strain, D.D. Richman, M.G. Hudgens, R.J. Bosch, J.M. Coffin, J.J. Eron, D.J. Hazuda, and D.M. Margolis Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy Nature 487 2012 482 485
2. E. Ballana, and J.A. Este Insights from host genomics into HIV infection and disease: identification of host targets for drug development Antiviral Res. 100 2013 473 786
3. K.M. Barton, N.M. Archin, K.S. Keedy, A.S. Espeseth, Y.L. Zhang, J. Gale, F.F. Wagner, E.B. Holson, and D.M. Margolis Selective HDAC inhibition for the disruption of latent HIV-1 infection PLoS One 9 2014 e102684
4. A. Bosque, and V. Planelles Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells Methods 53 2011 54 61
5. K.M. Bruner, N.N. Hosmane, and R.F. Siliciano Towards an HIV-1 cure: measuring the latent reservoir Trends Microbiol. 23 2015 192 203
6. C.K. Bullen, G.M. Laird, C.M. Durand, J.D. Siliciano, and R.F. Siliciano New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo Nat. Med. 20 2014 425 429
7. T.-W. Chun, L. Carruth, D. Finzi, X. Shen, J.A. DiGiuseppe, H. Taylor, M. Hermankova, K. Chadwick, J. Margolick, T.C. Quinn, Y.-H. Kuo, R. Brookmeyer, M.A. Zeiger, P. Barditch-Crovo, and R.F. Siliciano Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection Nature 387 1997 183 188
8. A.R. Cillo, M.D. Sobolewski, R.J. Bosch, E. Fyne, M. Piatak Jr., J.M. Coffin, and J.W. Mellors Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy Proc. Natl. Acad. Sci. U.S.A. 111 2014 7078 7083
9. V. Dahl, L. Josefsson, and S. Palmer HIV reservoirs, latency, and reactivation: prospects for eradication Antiviral Res. 85 2010 286 294
10. S.G. Deeks HIV: shock and kill Nature 487 2012 439 440
11. J.A. Esté, and T. Cihlar Current challenges in antiretoviral research and treatment Antiviral Res. 85 2010 26 33
12. D. Finzi, M. Hermankova, T. Pierson, L.M. Carruth, C. Buck, R.E. Chaisson, T.C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D.D. Ho, D.D. Richman, and R.F. Siliciano Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy Science 278 1997 1295 1300
13. D. Finzi, J. Blankson, J.D. Siliciano, J.B. Margolick, K. Chadwick, T. Pierson, K. Smith, J. Lisziewicz, F. Lori, C. Flexner, T.C. Quinn, R.E. Chaisson, E. Rosenberg, B. Walker, S. Gange, J. Gallant, and R.F. Siliciano Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy Nat. Med. 5 1999 512 517
14. G. Giannini, L. Vesci, G. Battistuzzi, D. Vignola, F.M. Milazzo, M.B. Guglielmi, M. Barbarino, M. Santaniello, N. Fanto, M. Mor, S. Rivara, D. Pala, M. Taddei, C. Pisano, and W. Cabri ST7612AA1, a thioacetate-omega(gamma-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors J. Med. Chem. 57 2014 8358 8377
15. G. Jiang, A. Espeseth, D.J. Hazuda, and D.M. Margolis C-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter J. Virol. 81 2007 10914 10923
16. A. Jordan, D. Bisgrove, and E. Verdin HIV reproducibly establishes a latent infection after acute infection of T cells in vitro EMBO J. 22 2003 1868 1877
17. Z. Klase, V.S. Yedavalli, L. Houzet, M. Perkins, F. Maldarelli, J. Brenchley, K. Strebel, P. Liu, and K.T. Jeang Activation of HIV-1 from latent infection via synergy of RUNX1 inhibitor Ro5-3335 and SAHA PLoS Pathog. 10 2014 e1003997
18. G.M. Laird, C.K. Bullen, D.I. Rosenbloom, A.R. Martin, A.L. Hill, C.M. Durand, J.D. Siliciano, and R.F. Siliciano Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations J. Clin. Invest. 125 2015 1901 1912
19. J. Lan, K. Yang, D. Byrd, N. Hu, T. Amet, N. Shepherd, M. Desai, J. Gao, S. Gupta, Y. Sun, and Q. Yu Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells J. Immunol. 193 2014 3577 3589
20. R. Mitsuyasu Curing HIV: lessons from cancer therapy Curr. Opin. HIV AIDS 8 2013 224 229
21. G. Moncunill, M. Armand-Ugon, I. Clotet-Codina, E. Pauls, E. Ballana, A. Llano, B. Romagnoli, J.W. Vrijbloed, F.O. Gombert, B. Clotet, S. De Marco, and J.A. Este Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026 Mol. Pharmacol. 73 2008 1264 1273
22. E. Pauls, E. Jimenez, A. Ruiz, M. Permanyer, H. Costa, R. Nascimiento, M. Parkhouse, R. Peña, E. Riveiro-Muñoz, M.A. Martinez, B. Clotet, J.A. Esté, and M. Bofill Restriction of HIV-1 replication in primary macrophages by interleukin-12 and interleukin-18 through the upregulation of SAMHD1 J. Immunol. 190 2013 4736 4741
23. E. Pauls, R. Badia, J. Torres-Torronteras, A. Ruiz, M. Permanyer, E. Riveira-Muñoz, B. Clotet, R. Marti, E. Ballana, and J.A. Esté Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile [alpha] motif and HD domain-containing protein-1 activity AIDS 28 2014 2213 2222
24. E. Pauls, A. Ruiz, R. Badia, M. Permanyer, A. Gubern, E. Riveira-Muñoz, J. Torres-Torronteras, M. Álvarez, B. Mothe, C. Brander, M. Crespo, L. Menéndez-Arias, B. Clotet, O.T. Keppler, R. Martí, F. Posas, E. Ballana, and J.A. Esté Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells J. Immunol. 193 2014 1988 1997
25. T.A. Rasmussen, M. Tolstrup, H.J. Moller, C.R. Brinkmann, R. Olesen, C. Erikstrup, A.L. Laursen, L. Ostergaard, and O.S. Sogaard Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system Open Forum Infect. Dis. 2 2015 ofv037
26. S. Saleh, A. Solomon, F. Wightman, M. Xhilaga, P.U. Cameron, and S.R. Lewin CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency Blood 110 2007 4161 4164
27. L. Shan, S.A. Rabi, G.M. Laird, E.E. Eisele, H. Zhang, J.B. Margolick, and R.F. Siliciano A novel PCR assay for quantification of HIV-1 RNA J. Virol. 87 2013 6521 6525
28. H.T. Shang, J.W. Ding, S.Y. Yu, T. Wu, Q.L. Zhang, and F.J. Liang Progress and challenges in the use of latent HIV-1 reactivating agents Acta Pharmacol. Sin. 36 2015 908 916
29. J.D. Siliciano, J. Kajdas, D. Finzi, T.C. Quinn, K. Chadwick, J.B. Margolick, C. Kovacs, S.J. Gange, and R.F. Siliciano Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells Nat. Med. 9 2003 727 728
30. L. Vesci, E. Bernasconi, F.M. Milazzo, R. De Santis, E. Gaudio, I. Kwee, A. Rinaldi, S. Pace, V. Carollo, G. Giannini, and F. Bertoni Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor Oncotarget 6 2015 5735 5748
31. D.G. Wei, V. Chiang, E. Fyne, M. Balakrishnan, T. Barnes, M. Graupe, J. Hesselgesser, A. Irrinki, J.P. Murry, G. Stepan, K.M. Stray, A. Tsai, H. Yu, J. Spindler, M. Kearney, C.A. Spina, D. McMahon, J. Lalezari, D. Sloan, J. Mellors, R. Geleziunas, and T. Cihlar Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing PLoS Pathog. 10 2014 e1004071
32. F. Wightman, H.K. Lu, A.E. Solomon, S. Saleh, A.N. Harman, A.L. Cunningham, L. Gray, M. Churchill, P.U. Cameron, A.E. Dear, and S.R. Lewin Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells AIDS 27 2013 2853 2862
33. S.A. Williams, L.F. Chen, H. Kwon, C.M. Ruiz-Jarabo, E. Verdin, and W.C. Greene NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation EMBO J. 25 2006 139 149